Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications | MicrobiomeTrials
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-04-23Est. Completion: 2027-12
Enrollment target: 380 participants
Locations
Clinical Innovations, Inc. dba CITrials, Bellflower, California, United States
ProScience Research Group, Culver City, California, United States
Collaborative Neuroscience Research, LLC, Garden Grove, California, United States
Clinical Innovations, Inc. dba CITrials, Riverside, California, United States
Velocity Clinical Research, Hallandale Beach, Hallandale, Florida, United States
Behavioral Clinical Research, Inc., Hollywood, Florida, United States
ForCare Clinical Research, Tampa, Florida, United States
Atlanta Center for Medical Research, LLC, Atlanta, Georgia, United States
CenExel iResearch, LLC, Decatur, Georgia, United States
CBH Health, LLC dba CenExel, Gaithersburg, Maryland, United States
Hassman Research Institute, LLC dba CenExel, Marlton, New Jersey, United States
New York State Psychiatric Institute, New York, New York, United States
Pillar Clinical Research, LLC, Richardson, Texas, United States
Other microbiome trials you might be interested in